ACTRN12618001390279已完成1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics and Food Effect of Single Ascending Doses and Multiple Ascending Doses of EHP-101 in Healthy Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 104
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1. Healthy male or female subjects greater than or equal to 18 to less than or equal to 65 years of age.
- •2. Body mass index (BMI) range 18 to 34 kg/m^2.
- •3. Free from any clinically significant abnormality on the basis of medical history, vital signs, physical examination, 12-lead electrocardiogram (ECG), echocardiography, ophthalmologic examinations and tests, and laboratory evaluations at screening and admission, as judged by the Investigator.
- •4. Cardiac Troponin I level below the upper limit of normal, as defined by the manufacturer.
- •5. Ability to understand and the willingness to provide informed consent for participation in the study.
- •6. Ability and willingness, as judged by the Investigator, to comply with all study requirements.
排除标准
- •1. Any known, documented, or suspected history of:
- •a) schizophrenia or other psychotic illness, or diagnosis of schizophrenia in a first-degree relative.
- •b) alcohol or substance abuse within the last 2 years before screening or positive test result(s) for alcohol and or drugs of abuse.
- •c) Regular alcohol consumption greater than 21 units per week
- •2. Use of nicotine or nicotine-containing products during participation in the study.
- •3. Caffeine consumption is limited to no more than 2 units per day.
- •4. Any known, documented, or suspected hypersensitivity to cannabinoids or any of the excipients of EHP-101 Liquid.
- •5. Use of cannabis or cannabinoid-based medications.
- •6. Abnormal screening 12-lead ECG interpreted by the Investigator to be clinically significant.
- •7. Presence of ophthalmologic abnormalities at baseline, specifically known closed angles, previous laser iridotomy, or severe hypermetropic diagnosis.
- •8. Male subjects who are not surgically sterilized and who do not agree to use condoms in combination with partner use of a highly effective method of contraception. Female subjects of childbearing potential who are not using a highly effective method of contraception, as judged by the Investigator, and who do not consent: i) to use a combined barrier method of contraception and ii) to remain on a highly effective method of contraception while receiving study intervention during the study and for at least 90 days after the end of study treatment.
- •9. Female subjects who are pregnant, lactating, or planning pregnancy during the course of the study and for 12 weeks thereafter.
- •10. Male subjects unwilling to abstain from sperm donation during the study and for 12 weeks thereafter.
- •11. Any evidence or history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV types 1 and 2) infection.
- •12. Subjects who have received an IP within the 12 weeks before the screening visit.
- •13. Blood donation or loss (eg, greater than or equal to 400 mL) within 3 months before enrollment and unwilling to abstain from blood donation during the study.
- •14. Significant disease or disorder, which, in the opinion of the Investigator or other staff who is directly involved in the study, may either put the subject at risk because of participation in the study or interfere with the subject's ability to participate in the study.
- •15. Intake of any metabolic enzyme-affecting drugs from 30 days prior to Day -1 (ie, Check-in).
- •16. Vaccination within 30 days prior to enrollment.
研究者
相似试验
已完成
不适用
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Day Dose Study to Assess the Safety and Tolerability of JNJ-67670187 in Healthy ParticipantsUlcerative colitisIBDNL-OMON47984Janssen-Cilag International NV98
已完成
1 期
A First-in-Human Phase 1 Study to evaluate the Safety and Tolerability of Single ascending doses of GSBR-1290 in Healthy Adult participants.Type 2 Diabetes MellitusACTRN12622000084785Gasherbrum Bio Pty Ltd. (Australian entity of ShouTi Inc)48
已完成
不适用
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX105 in Normal Healthy VolunteersNeurological- and autoimmune disorders1000381610029305NL-OMON53467Annexon, Inc.48
终止
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Oral ACH-0143422 after Single and Multiple-ascending Doses in Health Volunteers and Subjects With Chronic Hepatitis C Virus Genotype 1 Infection.This current study is being conducted in healthy volunteers to learn about the way this drug behaves in the body when it is given at different doses. The study will also be conducted in patients with Hepatitis C genotype 1.Infection - Other infectious diseasesACTRN12614000304639Achillion Pharmaceuticals, Inc157
已完成
1 期
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of AR882 in Healthy Adult Male VolunteersHyperuricemiaACTRN12619000908134Arthrosi Therapeutics Australia Pty, Ltd a subsidiary of Arthrosi Therapeutics, Inc.30